{"filings":[{"id":1278807,"accession_number":"0001193125-26-282989","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-06-25T21:00:13+00:00","items":["5.07"],"status":"ready","headline":"Coya Therapeutics stockholders elect Wilbur Ross and Dieter Weinand as Class I directors, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Wilbur Ross elected as Class I director with 9,168,496 for, 2,818,233 against, 4,585,732 broker non-votes.","Dieter Weinand elected with 10,566,702 for, 1,420,027 against, 4,585,732 broker non-votes.","Ratification of Weaver & Tidwell as independent auditor passed with 16,545,887 for, 22,661 against, 3,913 abstain.","All proposals passed; no unexpected or contested items at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":23081,"accession_number":"0001193125-26-218282","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-05-12T12:48:29+00:00","items":["1.01","9.01"],"status":"ready","headline":"Coya Therapeutics enters $30M at-the-market equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with Leerink Partners allows up to $30M gross proceeds from common stock sales on Nasdaq.","Leerink receives 3.0% commission on gross proceeds; Company may sell at its discretion.","Offering under existing shelf registration; no minimum obligation to sell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22521,"accession_number":"0001193125-26-218198","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-05-12T11:39:12+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).","Cash and cash equivalents $50.7M as of March 31, 2026.","FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026.","ALSTARS Phase 2 trial now in full recruitment; topline readout expected Q1 2027.","Completed $11.1M private placement led by Dr. Reddy's ($10M) and Greenlight Capital ($1.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":251147.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96024,"accession_number":"0001193125-26-139094","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Coya Therapeutics founder Howard Berman steps down as Executive Chairman; Mark Pavao appointed independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Howard Berman resigned as Executive Chairman and Board member effective April 1, 2026; part of planned CEO transition initiated November 2024.","Separation agreement includes prorated 2026 bonus at 100% target, COBRA coverage through March 2027, and continued vesting of stock options for 12 months.","Mark H. Pavao appointed as independent Class III director, term expiring at 2028 annual meeting; granted option for 10,000 shares vesting in one year.","Pavao brings 30+ years of biopharma commercial experience, including roles at Bristol-Myers Squibb and R-Pharm US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109523,"accession_number":"0001193125-26-107276","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coya Therapeutics FY2025 net loss $21.2M; cash $46.8M, ALS trial enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $46.8M at Dec 31, 2025; collaboration revenue $7.9M (up from $3.6M).","R&D expenses $16.7M (up $4.8M); net loss $21.2M vs $14.9M in FY2024.","COYA 302 ALSTARS Phase 2 trial actively enrolling across ~25 sites in US and Canada.","FDA accepted IND for COYA 302 in frontotemporal dementia (FTD); Phase 2a expected 2H2026.","Completed $23M public offering and $11.1M private placement; cash runway into 2H2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109522,"accession_number":"0001193125-26-030531","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Coya Therapeutics raises $11.1M via private placement with Dr. Reddy's and Greenlight Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$11.1M from sale of 2,522,727 shares at $4.40 each; no broker/agent.","Dr. Reddy's Labs invests $10M, Greenlight Capital $1.1M; expected close Jan 30, 2026.","Proceeds to accelerate tech transfer and scale-up manufacturing for low dose IL-2 to support COYA 302.","Reiterates cash runway into H2 2027 and past projected ALSTARS trial topline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109521,"accession_number":"0001193125-26-016017","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics announces $46.8M cash, runway into H2 2027, ALSTARS readout Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash balance of $46.8M as of Dec 31, 2025 (unaudited), with projected runway into second half of 2027.","Company expects topline data readout from ALSTARS Phase 2 trial in first quarter of 2027.","Updates conveyed in letter to stockholders dated January 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109520,"accession_number":"0001193125-26-007042","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics reports positive proof-of-concept study results in Frontotemporal Dementia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9-patient open-label study of low-dose IL-2 + CTLA4-Ig showed no serious adverse events over 22 weeks.","Treg suppressive function and percentage significantly increased from week 2 through week 22.","MOCA scores stable (baseline 13.5, week 22: 14) and CDR-FTLD stable (4.8 vs 5.5), indicating no cognitive decline.","Study led by Houston Methodist Neurological Institute; funded by Peggy and Gary Edwards Endowment Fund.","Common adverse event was mild injection-site erythema (33.3%); all resolved spontaneously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126045,"accession_number":"0001193125-25-321737","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya receives $4.2M milestone from Dr. Reddy's for first ALS patient dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Milestone triggered by first patient dosed in ALSTARS trial of COYA 302 for ALS.","Dosing announced Dec 9, 2025; payment received Dec 16, 2025.","Payment under Dec 2023 Development and License Agreement with Dr. Reddy's Labs.","COYA 302 is an investigational therapy targeting amyotrophic lateral sclerosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126044,"accession_number":"0001193125-25-276022","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics reports Q3 net loss of $2.1M; IND accepted for COYA 302 in ALS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M for Q3 2025 improved from $4.0M loss in Q3 2024; cash and equivalents at $28.1M.","FDA accepted IND for COYA 302 in ALS; ALSTARS Phase 2 trial launched with up to 25 sites.","Closed $23.0M upsized public offering; cash runway extended into second half of 2027.","Received $4.2M milestone from Dr. Reddy's for IND approval; additional $4.2M due on first dosing."],"consensus_eps_estimate":-0.2788,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3985754.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126043,"accession_number":"0001193125-25-250709","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics prices upsized public offering of 4.18M shares at $5.50, raising ~$23M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,636,364 shares (base) plus full exercise of 545,454 over-allotment, all at $5.50/share.","Gross proceeds of approximately $23.0 million; net proceeds for working capital and clinical development.","Directors and officers subject to lock-up restricting share sales until January 22, 2026.","Financial advisor to receive 100,000 warrants at $5.50 exercise price and $200,000 fee.","Lucid Capital Markets is sole book-runner; Allele Capital Partners acted as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142768,"accession_number":"0001193125-25-193450","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics receives $4.2M milestone from Dr. Reddy's for ALS IND acceptance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted IND for COYA 302 Phase 2 study in ALS, triggering $4.2M milestone from Dr. Reddy's Laboratories.","Additional $4.2M payment due upon first patient dosing in the Phase 2 study.","Phase 2 trial is randomized, double-blind, placebo-controlled, 24-week with 24-week open-label extension.","Milestone arises from Development and License Agreement signed December 5, 2023.","Payment signals progress in clinical development for COYA 302 combination therapy in ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142767,"accession_number":"0000950170-25-106932","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics Q2 2025 net loss $6.1M; cash $29.8M; FDA decision on COYA 302 ALS IND by Aug 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.1M vs $2.9M in Q2 2024; collaboration revenue fell to $0.2M from $3.4M.","Cash and equivalents $29.8M as of June 30, 2025.","R&D expenses $3.7M (down $0.9M YoY); G&A $2.9M (up $0.8M YoY).","FDA decision on IND for COYA 302 in ALS expected by August 29, 2025; upon acceptance, DRL milestone payment of $8.4M.","Additional catalysts: top-line data from FTD trial, IND for FTD by year-end."],"consensus_eps_estimate":-0.4007,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":421500.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142766,"accession_number":"0001193125-25-168115","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA delays IND review for COYA 302 ALS trial due to workload; decision expected by Aug 29, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Coya submitted IND for Phase 2 ALS study of COYA 302 on June 30, 2025.","FDA informed Coya on July 29, 2025, that it cannot meet initial July 30 review goal due to workload and resource constraints.","FDA expects to provide IND decision no later than August 29, 2025.","Delay affects timeline for starting the planned 24-week placebo-controlled study with 24-week OLE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142765,"accession_number":"0001193125-25-153465","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya re-submits IND for COYA 302 ALS Phase 2 study after FDA request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Re-submitted IND to FDA on June 30, 2025, including requested non-clinical data.","Previous FDA request on July 14, 2024, for additional non-clinical data.","Plans to initiate Phase 2 study upon IND acceptance.","Study: randomized, double-blind, placebo-controlled, 24-week with 24-week OLE, evaluating COYA 302 for ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160856,"accession_number":"0001193125-25-149104","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coya Therapeutics stockholder votes: three Class III directors elected, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Howard Berman (5,821,649 for, 505,761 withheld), Arun Swaminathan (6,324,520 for, 2,890 withheld), Ann Lee (5,779,312 for, 548,098 withheld) elected as Class III directors.","Ratification of Weaver and Tidwell as independent auditor approved: 10,355,085 for, 68,851 against, 340 abstentions.","Broker non-votes of 4,096,866 were present for director election items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160855,"accession_number":"0000950170-25-069819","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics Q1 net loss $7.3M; pipeline milestones for COYA 302 detailed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.3M in Q1 2025 vs $5.1M in Q1 2024; R&D expense rose to $5.2M from $3.1M.","Cash and cash equivalents $35.5M as of March 31, 2025.","Positive interim results from investigator-initiated trial of LD IL-2 + CTLA4-Ig in Frontotemporal Dementia.","Expects IND submission for COYA 302 in ALS in Q2 2025; $8.4M milestone from DRL due upon first dosing.","Plans to file IND for COYA 302 in FTD by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":257884.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179051,"accession_number":"0000950170-25-040779","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics FY2024 net loss $14.9M; cash $38.3M; pipeline updates for ALS and FTD trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.9M in 2024 vs $8.0M in 2023; R&D expenses $11.9M (up from $5.5M).","Cash and equivalents $38.3M as of Dec 31, 2024; raised $10M private placement and $5M from ADDF.","Received $3.85M from Dr. Reddy's for COYA-302 ALS Phase 2; eligible for additional $8.4M milestone.","Plan to submit nonclinical data to FDA in Q2 2025 for COYA-302 ALS Phase 2b trial initiation.","Expect to file IND for COYA-302 Phase 2b in FTD in 2H 2025; top-line data from investigator trial also in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195734,"accession_number":"0000950170-24-121833","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics Q3 net loss $4.0M, cash $39.8M post-raise; positive AD data, new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.0M in Q3 2024 (vs $3.4M prior); cash $31.1M (Sep) rose to $39.8M after capital raise.","Positive LD IL-2 data in mild-moderate Alzheimer's from investigator-initiated Phase 2 presented at CTAD24; patents filed for COYA 301/GLP-1 combo.","Arun Swaminathan appointed CEO effective Nov 1, 2024; Howard Berman transitions to Executive Chairman.","Aligned with FDA on non-clinical data for COYA-302 Phase 2b ALS trial; eligible for $8.4M milestone from Dr. Reddy's upon IND acceptance and dosing.","2025 catalysts: additional AD data Q1, ALS biomarker data Q2, FTD data 2H, and COYA-302 IND for FTD expected in 2H."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3552109.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195733,"accession_number":"0001193125-24-251319","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Hideki Garren resigns from Coya board effective Nov 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hideki Garren resigned immediately to comply with new employer's policy barring board service on companies with similar therapeutic areas.","Resignation was not due to any disagreement with Coya or its management on operations, policies, or practices.","Board seat vacancy created; no replacement announced as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195732,"accession_number":"0001193125-24-248755","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Coya Therapeutics appoints Arun Swaminathan as CEO, Howard Berman becomes Executive Chairman effective Nov 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Swaminathan employment agreement provides $525,000 base salary, eligible for annual bonus up to 50% of base.","Berman employment agreement provides $420,000 base salary, eligible for annual bonus up to 50% of base.","Swaminathan becomes CEO on Nov 1, 2024; Berman resigns as CEO on Oct 31, 2024, remains on Board as Executive Chairman.","Severance: if terminated without cause, 12 months base salary continuation plus prorated bonus for each.","Non-compete for Swaminathan: 6 months post-termination, restricted to IL-2, CTLA-4 Ig, exosome product companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195731,"accession_number":"0001193125-24-246171","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Coya Therapeutics: Phase 2 LD IL-2 in Alzheimer's meets endpoints, shows cognitive stabilization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study met primary safety endpoint and secondary endpoint for Treg expansion with no off-target effects.","LD IL-2 q4wks showed cognitive stabilization (ADAS-Cog14 4.93-point improvement vs placebo, p=0.061).","Significant improvement in CSF Aß42 (p=0.045) and trend toward stabilizing CSF NfL (p=0.060) with q4wks.","Company likely advancing LD IL-2 q4wks; supports COYA 302 combination in ALS and FTD.","No serious adverse events or deaths; common AEs were mild injection-site erythema and eosinophil increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195730,"accession_number":"0001193125-24-240775","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Coya raises $10M via private placement of 1,379,314 shares at $7.25; cash $31M as of Sep 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,379,314 shares at $7.25 per share; gross proceeds of ~$10.0M.","Majority of investors are existing institutional stockholders of Coya.","Net proceeds for general corporate, preclinical/clinical/regulatory activities.","Preliminary cash and cash equivalents of ~$31.0M as of Sep 30, 2024.","Closing expected on or about October 23, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212010,"accession_number":"0001193125-24-202551","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics promotes Arun Swaminathan to CEO effective Nov 1, 2024; Howard Berman becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arun Swaminathan, current CBO, promoted to CEO effective Nov 1, 2024; succeeds Howard Berman.","Howard Berman resigns as CEO effective Oct 31, 2024, remains as Executive Chairman and director.","Swaminathan appointed to Board of Directors as Class III director effective immediately.","Swaminathan led Dr. Reddy's licensing transaction worth up to $700M; executed over $6B in deals.","Company expects upcoming Alzheimer's data at CTAD24 on Oct 29, 2024; continues progress on COYA 302 in ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212009,"accession_number":"0000950170-24-095072","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Q2 net loss $2.9M; FDA demands more data before COYA 302 ALS Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.9M vs $3.1M YoY; collaboration rev $3.4M from Dr. Reddy's.","Cash $36.6M at June 30, 2024.","FDA requires additional non-clinical data before Phase 2 of COYA 302 in ALS; Coya plans to discuss in Q4 2024.","Received $5M strategic investment from ADDF for COYA 302 in FTD.","R&D expenses $4.6M (up from $1.1M) driven by preclinical costs for COYA 302."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":3552109.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212008,"accession_number":"0001193125-24-178809","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics FDA requires additional non-clinical data before initiating Phase 2 ALS trial for COYA 302","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted IND for Phase 2 double-blind, placebo-controlled study of COYA 302 in ALS on June 14, 2024.","FDA notified on July 12, 2024 that additional non-clinical data is required prior to study initiation.","FDA will provide details on required data within 30 days.","Study was designed as 24-week treatment phase with 24-week open-label extension.","Regulatory delay may push back clinical timeline for COYA 302."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230845,"accession_number":"0001193125-24-154729","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Coya gets $3.85M from Dr. Reddy's for COYA 302 Phase 2 trial; first $6M royalties waived","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Reddy's makes $3.85M one-time payment to Coya for funding first Phase 2 trial of COYA 302 in ALS.","Dr. Reddy's has no obligation to pay the first $6M in royalties otherwise due under the DRL Development Agreement.","Amendment effective June 4, 2024; payment due within 5 business days of Coya's invoice.","Funds must be used solely for the Phase 2 trial in the U.S. as per the Development Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230844,"accession_number":"0001193125-24-142950","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Coya receives $5M strategic investment from ADDF for COYA 302 FTD trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADDF purchased 603,136 shares at $8.29/share for $5M gross proceeds in private placement.","Funds will support COYA 302 development for frontotemporal dementia (FTD) Phase 2 trial.","ADDF, focused on Alzheimer's and related dementias, backs combination therapy approach.","Registration statement for resale of shares to be filed within 30 days and effective within 75 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230843,"accession_number":"0000950170-24-057018","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics Reports Q1 2024 Net Loss of $5.1M and Cash of $36.0M, Advances Pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss was $5.1M for Q1 2024 vs $2.7M in Q1 2023; R&D expenses rose to $3.1M from $1.2M.","Cash and cash equivalents totaled $36.0M as of March 31, 2024, providing runway into 2026.","IND filing for COYA 302 in ALS expected in 2Q24, with Ph. 2 trial initiation thereafter.","Pipeline expanded to include Frontotemporal Dementia, Parkinson’s, and Alzheimer’s diseases.","Licensed next-generation immune modulatory biologics from University of Nebraska Medical Center in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":126838.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230842,"accession_number":"0001193125-24-134376","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Coya Therapeutics stockholders approve 750,000 share increase to equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2021 Equity Incentive Plan adds 750,000 shares, raising total authorized to 2,571,070.","Class II directors elected: Anabella Villalobos, Ph.D. and Dov Goldstein, M.D., M.B.A.","Shareholders ratified Weaver and Tidwell, L.L.P. as independent auditor for FY2024.","All three proposals passed with required votes, including broker non-votes on director and plan items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249235,"accession_number":"0000950170-24-033159","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics reports FY2023 net loss of $8.0M; cash $32.6M plus $7.5M upfront from Dr. Reddy's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $8.0M in FY2023 from $12.2M in FY2022; R&D spend $5.5M, G&A $7.8M.","Cash and equivalents $32.6M at Dec 31, 2023; plus $7.5M upfront from Dr. Reddy's received Jan 2024.","Closed Jan 2023 IPO net $14.1M and Dec 2023 private placement net $24.0M.","Dr. Reddy's collaboration for COYA 302 in ALS: up to $733M milestones plus low-to-mid teens royalties.","IND for COYA 302 in ALS expected 2Q24; Ph.2 topline data targeted for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249234,"accession_number":"0001193125-24-010775","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics reports $32.6M cash at Dec 31, 2023; receives $7.5M from Dr. Reddy's in Jan 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $32.6M as of Dec 31, 2023; pro forma $40.1M after $7.5M received from Dr. Reddy's in Jan 2024.","Milestone payments: $4.2M upon FDA acceptance of IND for COYA 302 (ALS) and $4.2M upon first patient dosed in Phase 2.","Anticipates IND filing in H1 2024 and first patient dosing in H2 2024 for COYA 302 in ALS.","Company expects current cash runway to fund operations into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266718,"accession_number":"0001193125-23-299370","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics appoints former US Secretary of Commerce Wilbur L. Ross to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to seven directors; Ross appointed Class I director effective Dec 19, 2023, term until 2026 annual meeting.","Ross granted options for 10,000 shares at closing price on Jan 2, 2024, vesting on one-year anniversary of appointment.","Coya will leverage Ross's 55+ years of investment banking, private equity, and government experience for strategic partnerships and capital markets.","Ross served as 39th US Secretary of Commerce (2017-2021) and is former Chairman & CSO of WL Ross & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266717,"accession_number":"0001193125-23-289550","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Coya partners with Dr. Reddy's on COYA 302 for ALS; raises $26.5M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $7.5M from Dr. Reddy's; additional $4.2M upon IND acceptance and $4.2M upon first patient in Phase 2.","Potential development milestones up to $40M and sales milestones up to $677.25M; royalties in low to mid-teens.","Private placement of 4.37M shares at $6.06/share for gross proceeds ~$26.5M; expected to close Dec 11, 2023.","Former US Secretary Wilbur Ross participating in placement; expected to join board after closing.","COYA to lead clinical development and US regulatory for COYA 302; IND filing expected in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266716,"accession_number":"0000950170-23-060716","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya reports Q3 net loss $3.4M, cash $10.9M; Phase 2 AD topline due summer 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.4M ($0.34/share) vs $4.0M ($1.55/share) in Q3 2022; cash $10.9M up from $5.9M at Dec 2022.","R&D expenses $1.6M, G&A $2.0M; net loss per share improved due to increase in shares outstanding to 9.95M.","Completed enrollment (38 patients) in Phase 2 double-blind placebo-controlled trial of LD IL-2 in Alzheimer's; topline data expected summer 2024.","Plan to submit IND for Phase 2 trial of COYA 302 in ALS in 1H 2024; also licensed exosome engineering technology from Carnegie Mellon.","Appointed Dieter Weinand to board, Dr. Fred Grossman as President & CMO, and Dr. Merit Cudkowicz as clinical advisor in recent months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283966,"accession_number":"0001193125-23-217039","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Coya appoints former Bayer Pharma CEO Dieter Weinand to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands to 6 members; Weinand named Class I director effective August 18, 2023.","Weinand granted option to buy 10,000 shares at $3.43, vesting on one-year anniversary.","He joins audit and nominating/governance committees, committees expanded to 4 members.","Weinand is former CEO and Chairman of Bayer Pharma AG; current chairman of Replimune and others.","Coya expects to leverage his 25+ years of pharma experience for strategic guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283965,"accession_number":"0000950170-23-039348","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics Q2 2023 net loss $3.1M; highlights positive AD and ALS clinical data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.1M ($0.31 per share) for Q2 2023 vs $3.4M loss in Q2 2022.","Cash and equivalents $13.1M as of June 30, 2023, up from $5.9M at Dec 31, 2022.","Positive PoC data for ld IL-2 in Alzheimer's: statistically significant MMSE improvement and reduced neuroinflammation.","ALS study of COYA 302 halted disease progression at 24 weeks; pre-IND meeting with FDA planned for H2 2023.","Appointed Dr. Fred Grossman as President/CMO and Arun Swaminathan as CBO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283964,"accession_number":"0001193125-23-187328","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Coya Therapeutics appoints Dr. Fred Grossman as President and CMO; compensation terms disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $450,000/year; annual bonus target of 40% of base salary based on company/individual performance.","Two option grants of 74,069 each (start date and Jan 2024) vesting over 3 years; additional equity possible.","Severance: 9 months base salary plus 9 months accelerated vesting if terminated without cause or resigns for good reason.","Employment effective July 17, 2023; initial term 2 years with auto-renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283963,"accession_number":"0001193125-23-184752","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Coya Therapeutics: Dr. Adrian Hepner resigns as President/CMO, replaced by Dr. Fred Grossman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Fred Grossman appointed President and CMO effective July 17, 2023, succeeding Dr. Adrian Hepner who resigned.","Base salary $450,000/year; annual bonus target 40% of base salary based on company-set objectives.","Two option grants each for 74,069 shares (first on start date, second Jan 2024); 24,689 shares vest after 1 year, remainder over 24 months.","Employment agreement initial term of 2 years, auto-renews annually unless either party gives 30-day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303567,"accession_number":"0001193125-23-178604","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coya Therapeutics annual meeting: Garren elected director, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Hideki Garren elected Class I director with 3,414,906 for, 405,471 withheld, 221,601 broker non-votes.","Ratification of Weaver & Tidwell as independent auditor received 4,008,651 for, 31,504 against, 1,823 abstain.","All proposals passed at the June 28, 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303566,"accession_number":"0001193125-23-165406","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Coya CEO update: ALS POC shows disease halted 24wks; AD Phase2 data due Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["COYA 302 in ALS: disease progression halted to week 24 with minimal decline to week 48 on ALSFRS scale in open-label study.","COYA 301 in AD: cognitive function improved or stabilized; Treg function enhanced, cytokines reduced, neuroinflammation decreased.","Pre-IND meeting with FDA for COYA 302 planned fall 2023; IND submission early 2024 with Phase 2 trial to follow.","Academic double-blind Phase 2 trial of low-dose IL-2 in AD (funded by Gates Foundation) top-line data expected Q2 2024.","Appointed immunologist Dr. Guillaume Dorothee to SAB; hired Arun Swaminathan as business development executive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303565,"accession_number":"0001193125-23-151872","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics lock-up ends early for certain shareholders; trading begins May 23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters agreed to end 180-day lock-up for certain shares (excluding board, management, founders) effective May 23, 2023.","Shares became eligible for sale at market open on May 23, subject to affiliate trading limits, vesting, and insider trading policy.","Original lock-up started Dec 28, 2022; early release shortens restriction by ~7 months for these holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303564,"accession_number":"0001193125-23-145650","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Coya Therapeutics' COYA 301 shows improved cognition and Treg expansion in Phase 1 AD study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8 AD patients treated with monthly COYA 301 (low-dose IL-2) showed statistically significant improvement in MMSE scores (p=0.015) during treatment.","Treg percentage nearly doubled from 4.55% to 8.68% (p=0.0004); suppressive function increased from 46.6% to 79.5% (p=0.003).","Blood levels of pro-inflammatory cytokines IL-15, CCL2, and CCL11 were significantly lowered after each treatment cycle.","No serious adverse events; mild injection-site reactions and leukopenia; no patient discontinued the study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303563,"accession_number":"0000950170-23-020073","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coya Therapeutics Q1 net loss $2.7M; ALS data halt progression; Dr. Reddy's deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.7M ($0.28 per share) for Q1 2023 vs $1.7M loss in Q1 2022.","Cash and cash equivalents $16.3M as of March 31, 2023.","Positive proof-of-concept data for COYA 302 in ALS: halted disease progression at 24 weeks, minimal decline at 48 weeks.","Entered worldwide agreement with Dr. Reddy's: in-licensed abatacept biosimilar for COYA 302, out-licensed COYA 301 to Dr. Reddy's for certain territories.","Appointed Arun Swaminathan, Ph.D. as Chief Business Officer; plans to file IND for phase 2 ALS trial in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323228,"accession_number":"0000950170-23-010589","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coya Therapeutics reports FY2022 net loss of $12.2M; positive ALS data for COYA 302","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M for FY2022 vs $4.9M in FY2021; R&D expense rose to $4.4M from $2.5M.","Cash and cash equivalents $5.9M at Dec 31, 2022; IPO net proceeds of $14.5M received in Jan 2023.","Positive proof-of-concept data for COYA 302 in ALS: halted disease progression over 6 months in 4 patients.","Entered worldwide agreement with Dr. Reddy's to in-license abatacept biosimilar and out-license COYA 301.","Anticipates IND filing for COYA 301 in FTD and COYA 302 in neurodegenerative diseases in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323227,"accession_number":"0001193125-23-076795","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Coya Therapeutics in-licenses Dr. Reddy's Abatacept biosimilar for COYA 302; $350K upfront, up to $22.7M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive License and Supply Agreement with Dr. Reddy's for Abatacept biosimilar, effective April 1, 2023.","Upfront payment of $350,000; potential development, regulatory and sales milestones up to ~$22.7 million.","COYA 302 combines Coya's low-dose IL-2 (COYA 301) with the biosimilar for neurodegenerative diseases.","Coya responsible for development; Dr. Reddy's for manufacture and supply of biosimilar.","Agreement covers U.S., Canada, Mexico, South America, EU, UK, Japan; cross-license for COYA 301 in other territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323226,"accession_number":"0001193125-23-075260","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Coya reports positive proof-of-concept data for COYA 302 in ALS; Treg function up, biomarkers down, ALSFRS stable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Treatment with IL-2/CTLA4-Ig (COYA 302) over 48 weeks significantly increased Treg suppressive function and Treg numbers in 4 ALS patients.","Biomarkers of oxidative stress (4-HNE, ox-LDL) were reduced; mean ALSFRS-R scores not statistically different from baseline, suggesting disease stabilization.","Adverse events limited to mild injection site reactions; no deaths or serious AEs; all 4 patients completed the study.","Study is open-label, single-arm, proof-of-concept; data supports further development of COYA 302 for ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323225,"accession_number":"0001193125-23-068453","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Coya Therapeutics confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company states it does not hold deposits, securities, or accounts at SVB.","No banking relationship of any kind exists with Silicon Valley Bank.","Clarification issued on March 13, 2023, amid SVB collapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323224,"accession_number":"0001193125-23-056314","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coya Therapeutics grants stock options to CEO, President/CMO, and CFO/COO","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Howard Berman granted options to purchase 165,000 shares at $3.85 per share.","President/CMO Adrian Hepner and CFO/COO David Snyder each granted options for 115,000 shares.","Options vest in 36 equal monthly installments with full acceleration on change of control.","Options expire 10 years from grant date; exercise price equals closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323223,"accession_number":"0000950170-23-001185","cik":1835022,"company_name":"Coya Therapeutics, Inc.","ticker":"COYA","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coya Therapeutics issues 237,804 more shares through partial IPO over-allotment exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 237,804 shares of common stock and warrants for 145,000 shares upon partial over-allotment exercise, closing January 25, 2023.","Total offering: 3,287,804 shares and warrants for 1,670,000 shares; gross proceeds of approx. $16.4 million.","Issued underwriters an additional five-year warrant to purchase 16,646 shares at $6.25 per share.","Chardan Capital Markets and Newbridge Securities acted as joint book-running managers; Joseph Gunnar as co-manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":109545047.63522013,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-25T23:59:59+00:00|323223"}